Market Intelligence, Clinical Progress, and High-Purity Reagents for Adenosine Deaminase (ADA) Targeting in Severe Combined Immunodeficiency (SCID) and Immuno-Oncology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADA Recombinant Protein (WT & SCID mutants). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View ADA Products |
| Gene Delivery | ADA Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and gene expression profiling. | View ADA Products |
| Benchmark Ab | Anti-ADA Monoclonal/Biosimilar Antibody. Recombinant positive control for ELISA/Western and binding assays. | View ADA Products |
| Validator | ADA siRNA Set. For knockdown verification in cell-based screening. | View ADA Products |
| Related Target A | CD39 (ENTPD1). ATP-to-AMP rate-limiting enzyme; upstream adenosine generator. | View CD39 Products |
| Related Target B | CD73 (NT5E). AMP-to-adenosine converting enzyme; primary adenosine generator in TME. | View CD73 Products |
| Related Target C | A2AR (ADORA2A). Adenosine receptor mediating immune suppression. | View A2AR Products |
| Related Target D | DPP4 / CD26. Primary ADA-binding ectoenzyme; co-target for immune modulation. | View DPP4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Replacement Therapy (ERT) Half-life Optimization | Recombinant ADA proteins expressed in HEK293 (native glycosylation) with theoretical MW for baseline stability testing. |
| Isoform Selectivity Screening (ADA1 vs. CECR1/ADA2) | Sequence-verified ADA and CECR1 proteins with >95% purity for parallel inhibition assays. |
| Cross-Species Preclinical Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available; HEK293 expressed with >95% purity for cross-reactivity profiling. |
| Lack of Reliable Controls | Clinical-grade benchmark anti-ADA antibodies and validated siRNA for assay calibration. |
| Target Specificity in High-Throughput Screening | Sequence Verified siRNA and specific antigens strictly verified by mass spectrometry to eliminate false positives. |
| Enzyme Activity Standardization | Endotoxin-controlled (<1 EU/ug) proteins with theoretical MW confirmed by mass spec consistency for reproducible kinetic assays. |
Key Mutations and Variants
Key mutations impacting ADA function and drug response:
- Allele ADA*2 (rs73598374): Polymorphism found in ~10% of the population; affects duration and intensity of enzyme activity (UniProt VAR_002209).
- rs121908725 (p.Gly216Arg): Loss-of-function mutation causing ADA-SCID (UniProt VAR_002210).
- rs121908724 (p.Arg211Gln): Loss-of-function mutation causing ADA-SCID (UniProt VAR_002211).
High-purity mutant proteins are available at TarMart for selectivity and resistance profiling.
Live ADA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ADA is uniquely bifurcated between rare disease (ADA-SCID) and tumor immunology (adenosine metabolic axis). Historically, Enzyme Replacement Therapy (ERT) with PEGylated bovine ADA (e.g., Revcovi from Leadiant) and autologous stem cell gene therapy (e.g., Strimvelis from Orchard Therapeutics) have been the standard for severe combined immunodeficiency. Meanwhile, the approved small-molecule inhibitor pentostatin (Pfizer/Hospira) remains the clinical anchor for hairy cell leukemia, but its narrow therapeutic index and lack of isoform selectivity have driven demand for next-generation inhibitors with improved ADA1/ADA2 discrimination.
Looking forward, the focus is expanding toward the broader adenosine immunoregulatory axis in oncology. Inhibiting adenosine accumulation by targeting ADA together with CD39, CD73, and A2AR is emerging as a compelling combination strategy to overcome immunotherapy resistance in solid tumors. Recombinant ADA variants engineered for microenvironment-specific delivery (“adenosine sink”) are also under preclinical investigation. Future R&D will likely converge on combination regimens that precisely tune adenosine flux through the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement Therapy (ERT) | Leadiant Biosciences | ADA-SCID | In vitro stability and potency testing (Need high-purity, native-glycosylation Recombinant Proteins) |
| Gene Therapy | Orchard Therapeutics | ADA-SCID | Expression validation and comparability assays (Need Lentivirus/ORF for stable cell construction) |
| Small Molecule Inhibitors | Pfizer, Generic Manufacturers; Emerging Biotech | Hairy Cell Leukemia, T-Cell Malignancies, Autoimmune Disease | Isoform selectivity assay (Need sequence-verified Wild-Type and mutant ADA proteins) |
| Immuno-Oncology Combinations | AstraZeneca, Corvus, Arcus | Solid Tumors (TME) | Pathway screening and rescue/knockdown assays (Need ADA lentivirus, siRNA, and related targets: CD73, CD39, A2AR) |
About TarMart Reagents
TarMart provides a comprehensive assay toolkit for ADA research: recombinant proteins (WT, mutants, orthologs) with native HEK293 glycosylation, >95% purity, and <1 EU/ug endotoxin; gene delivery tools (lentivirus, ORF clones); benchmark antibodies; and validated siRNA sets. All products are sequence-verified and quality-controlled to support drug discovery from target validation to preclinical development.